

## Disclosures

### Personal Commercial (4)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<b>Self</b>			
Boston Scientific Corporation	Research/Research Grants <i>‡ PI for clinical trial - HI-PEITHO and other investigator initiated trials.</i>	None (\$0)	Vascular Medicine
Boston Scientific Corporation	Consultant Fees/Honoraria	Significant (>= \$5,000)	Vascular Medicine
Brigham and Women's Hospital/ bristol myers squibb	Research/Research Grants <i>‡ COVID-19 Registry to Assess Frequency, Risk Factors, Management, and Outcomes of Arterial and Venous Thromboembolic Complications (CORONA-VTE NETWORK)</i>	None (\$0)	Vascular Medicine
Vascular Medcure, Inc.	Research/Research Grants <i>‡ CAPERE™ POST-MARKET CLINICAL FOLLOW-UP STUDY</i>	None (\$0)	Pulmonary Hypertension and Venous Thromboembolic

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (6)

Trial Name	Trial Sponsor	Trial Funding Source
Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2)	National Institutes of Health	
Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis - Hemodynamics (CREST-H)	National Institutes of Health	
Chronic Venous Thrombosis: Relief with Adjunctive Catheter-Directed Therapy	NIH- Uni of Washington	
The RESCUE Study	Thrombolex Inc	
A Double Blind, Randomized Trial of Airocumab and Plaque Regression in Peripheral Arterial Disease	UVA	
CAPERE – CAPTURE OF ACUTE PULMONARY EMBOLISM AND REMOVAL USING THE CAPERE® EMBOLECTOMY SYSTEM	Vascular Medcure Inc	

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

*† Commercial Funding Source | ‡ Trial Name*

## Agreement

### Certified Education Attestation

 | Signed on 10/12/2023  
 URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

### Confidentiality, Disclosure and Assignment Agreement

 | Signed on 10/12/2023  
 URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

### Embargo

 | Signed on 10/12/2023  
 URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

### On-Going Obligation Agreement

| Signed on 10/12/2023

## **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.